Prologue Medicines

Prologue Medicines, founded in 2021 and based in Cambridge, Massachusetts, is a Flagship Pioneering venture focused on harnessing viral evolution for drug discovery. The company's DELVE platform computationally mines the massive and growing database of viral proteins—over 6 million identified to date—to find novel biologics with therapeutic potential beyond the human proteome. Led by a seasoned team with deep computational and biopharma experience, Prologue is in the pre-clinical stage, aiming to rapidly translate viral protein discoveries into transformative medicines for a wide range of diseases. As a private, pre-revenue company, its success hinges on validating its platform and advancing its first programs into the clinic.

DELVE (Decoding Evolutionary Logic of Variant Ensembles) Platform: A computationally powered, scalable platform that mines the viral proteome using machine learning and next-generation sequencing to discover viral proteins with therapeutic potential and decode their design rules.

Prologue competes in the broad and competitive fields of AI-driven drug discovery and novel biologic modality development. Competitors include other Flagship companies and biotechs using computational methods to mine non-human proteomes (e.g., venoms, bacteriophages). Large pharma are also investing heavily in AI/ML for discovery, making the landscape crowded and fast-moving.